1. An oligonucleotide encoding a gene which is capable of regulating the synthesis of abscisic acid and encoding an amino acid sequence consisting of from M at the 1-position to I at the 164-position of the amino acids in the sequence represented by SEQ ID NO:2 in Sequence Listing, or oligonucleotides containing an oligonucleotide encoding an amino acid sequence derived from the above-described amino acid sequence by deletion, substitution or addition of one or several amino acids; products of these oligonucleotides; and vectors and plants containing these oligonucleotides.

2. Antisense oligonucleotides for spinocerebellar Ataxias

3. Pharmaceutical compounds comprising abasic oligonucleotides

4. Also provided are conjugates between abasic oligonucleotides and various immunostimulatory nucleic acids, including CpG oligonucleotides, as well as methods of use thereof.

5. We have developed a second-generation Antisense oligonucleotide (ISIS 25302) specific for murine TNF-alpha and have evaluated this oligonucleotide in …

6. We have shown that the splicing of a refractory exon, SMN2 exon 7, could be increased in fibroblasts derived from patients with spinal muscular atrophy by using Bifunctional targeted oligonucleotide enhancers of splicing (TOES) oligonucleotides that anneal to the exon and …

7. Antisense oligonucleotide-based therapeutics involves downregulation of gene expression

8. The adaptor may be a cholesterol-linked DNA adapter oligonucleotide.

9. Stretch-activated cation channel and antisense oligonucleotides thereto

10. Bio-Synthesis offers dSpacer Abasic oligonucleotide modification at various scales

11. Antisense oligonucleotides (ASOs) are short oligonucleotides that localize to the nucleus and provide a pathway for gene silencing by the RNase H pathway

12. Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides as active ingredients

13. DSpacer is commonly used to mimic an Abasic site in an oligonucleotide

14. Adaptor A short synthetic oligonucleotide which creates an internal restriction endonuclease site

15. 13 The double-stranded oligonucleotide was then purified by polyacrylamide gel electrophoresis.

16. These oligonucleotides thus comprise a therapeutic potential for treating pancreatic tumors.

17. Avidity is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.

18. In this review we will focus on the mechanisms of action of Antisense oligonucleotides

19. Oligonucleotides are transferred in the cells under the influence of shock waves.

20. Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide-based therapies in order to treat a wide range of serious diseases.

21. Antisense oligonucleotides are synthetic stretches of DNA which hybridize with specific mRNA strands

22. The experimental drug, Ionis-HTTRx, is a type of drug called “Antisense oligonucleotides”

23. The Azides are offered in 25 and 100 µmole packs for convenient oligonucleotide labeling

24. Oligonucleotides are disclosed that have increased binding affinity as shown by molecular modeling experiments.

25. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance.

26. Formation of non-covalent complexes between Amphipathic peptides and oligonucleotides is driven by electrostatic and hydrophobic interactions

27. 2 The world's lingering,the end is still no match for the forget the bitter oligonucleotide soup.

28. Methods controlling the activation of stem-loop oligonucleotides are within the scope of the invention.

29. A general method for the photochemical generation of ribose Abasic sites within RNA oligonucleotides is reported

30. Reported here is the synthesis of oligonucleotides containing a 2'-Acylamido-2'-deoxyuridine residue at their 3'-terminus

31. An oligonucleotide containing a synthetic nucleic acid such as BNA is preferred because of the high stability thereof.

32. This invention discloses high-affinity oligonucleotide ligands to the thermostable $i(Taq) polymerase and $i(Tth) polymerase.

33. Antisense oligonucleotides (ASOs) have been validated as therapeutic agents and an important tool in molecular biology

34. The incorporation of these modified phosphoroamidite analogues in oligonucleotide sequences can simulate the lesions occurring on the DNA strands.

35. The captured viral RNA target is then hybridized to Branched oligonucleotides (hence the name ‘Branched’ DNA assay

36. Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases

37. Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms

38. DNA Abasic sites The dSpacer (1,2'-Dideoxyribose) modification (Figure 1A) can be used to insert a single base space into a DNA oligonucleotide sequence

39. Reported here is the synthesis of oligonucleotides containing a 2‘-Acylamido-2‘-deoxyuridine residue at their 3‘-terminus

40. Using synthetic Antisense oligonucleotides, it targets genes at the level of mRNA, rather than DNA, and prevents them from producing proteins.

41. The PCR fragment Corresponded to the product of amplification between the oligonucleotides ropB1UP (5'ggccgtctgaaCTGTCCGAAGCCCAACAAAAC- TCTTGG3") and rpoBR1.

42. 28 The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo.

43. In the manufacturing of DNA oligonucleotides, in a pharmaceutical field and in photographic film, Acetonitrile is used as a solvent

44. Antisense oligonucleotides are used in treatment of oncology, diabetes, asthma, hair loss, and as Central Nervous System (CNS) therapeutics and …

45. Two of the more promising platforms are the Antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), both of which are often directed against similar targets.

46. Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.

47. In differential helical phasing experiments, synthetic oligonucleotides are prepared in which the distance of specific structural elements is systematically varied.sentencedict .com

48. Amphoteric liposome carriers for systemic delivery of oligonucleotides were developed using the new lipids and a methodology that predicts the stability and efficacy of liposomes.

49. Many of these schemes use a covalent attachment scheme, using oligonucleotides with amide or thiol functional groups as a chemical handle to bind the heteroelements.

50. Our Antisense therapies, also known as Antisense oligonucleotides, or ASOs, are designed to bind precisely with RNA, halting the process of creating a disease-causing protein.

51. aptus: fit) is a short single stranded DNA or RNA oligonucleotide, able to bind a target molecule specifically and with high affinity accordingly to its three dimensional structure.

52. There are few disease-modifying therapeutics for neurodegenerative diseases, but successes on the development of Antisense oligonucleotide (ASO) therapeutics for spinal muscular atrophy and Duchenne muscular dystrophy predict a robust future for ASOs in medicine

53. We also investigated the impact of the direct lipid conjugation to oligonucleotides 34 (anti miRNA 35 or Antisenses 24) on their activity and/or delivery in eukaryotic cells

54. Antisense oligonucleotides (ASOs) are small nucleotides that selectively bind and silence the expression of a specific gene's mRNA and have been recognized as an attractive potential strategy to

55. The novel peptides and oligonucleotides are of use in medicine for the treatment of conditions whose underlying aetiology is associated with $g(z)-PKC activity, for example tumours, hyperproliferative disorders and viral infections.

56. RNA-based drugs that include Antisense oligonucleotides bear great therapeutic potential toward treatment of various diseases by altering RNA and/or reducing, restoring, and modifying protein expression through multiple molecular mechanisms.

57. The Buccal mucosa, however, while avoiding first-pass effects, is a formidable barrier to drug absorption, especially for biopharmaceutical products (proteins and oligonucleotides) arising from the recent advances in genomics and proteomics.

58. Markers for each component were developed using decamer oligonucleotide primers 14).Hairy root cultures of Astragalus have been established and produced cycloartane saponins 15).Saponin is the major chemical constituent type in the Astragalus …

59. The present invention relates to highly specific oligonucleotide primers and probes useful in a rapid and specific method for detecting the presence of Group B Streptococcal (GBS) or Streptococcus agalactiae infection in a biological sample.

60. Biopharmaceutical A generic term for a biomolecule (e.g., proteins), including antibodies and nucleic acids and antisense oligonucleotides, which are produced in a transgenic organism—e.g., mice, livestock, fish, or plant—and used as a therapeutic agent

61. N-Myc, with its restricted expression in non-fetal tissues, is a therapeutic target to treat rhabdomyosarcomas, and blocking gene transcription using Antigene oligonucleotide strategies has therapeutic potential in the treatment of cancer and other diseases that …

62. To test this hypothesis, 34 human specimens obtained during carotid endarterectomy or bypass procedures were examined by use of specific oligonucleotide primers for Porphyromonas gingivalis, Prevotella intermedia, Actinobacillus actinomycetemcomitans and Bacteroides forsythus in polymerase chain reaction (PCR) assays.

63. Antisenses against WT1 which comprise oligonucleotide derivatives containing 1 or more sugar-modified nucleotide analog units represented by the following general formula (2) wherein B represents a pyrimidine nucleic acid base, a purine nucleic acid base or an analog thereof.

64. Antisense therapies (Antisense oligonucleotides or ASOs) are designed to bind precisely with RNA, halting the process of creating a disease-causing protein — disrupting diseases and changing their course—from the rarest of conditions, to those that impact millions of people.

65. These sugar modified oligonucleotides have the potential to be used as antisense therapies since they are expected to enhance nuclease resistance and cellular uptake while they maintain sequence-specificity and affinity to nucleic acid targets $i(in vitro) or $i(in vivo).

66. The first to enter in clinic has been Vitravene an Antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen) for the treatment of age-related macular degeneration (AMD).

67. Bacterial colonies were pooled and harvested, chromosomal DNA extracted and analysed by negative selection PCR for the presence of individual mutant DNA by using oligonucleotide primers specific for Tn10d-cat (blainv and Blarev) in combination with genome specific primers , which were designed to bind 100–1000 bp adjacent to the corresponding

68. B) examine the functional roles of DRA in anion transport by transfection of DRA cDNA in 293 cells (human embryonic kidney line) which lacks the endogenous Cl-HCO3 exchange activity; and c) To confirm the transport role of DRA in apical sulfate/oxalate or CL-HCO3 transport via utilizing Antisenses oligonucleotides designed against the DRA cDNA

69. A method of detecting a methylated cytosine of the invention comprises the steps of: hybridizing an oligonucleotide capable of hybridizing to a region containing a cytosine which is expected to be methylated in a sample DNA and having an abasic site at a position complementary to the cytosine to the sample DNA; oxidizing a methylated cytosine by reacting an oxidizing agent with the hybridized sample DNA formed in the previous step when a methylated cytosine is present therein; and detecting the oxidized methylated cytosine.

70. The conjugated medicinal agent of the present invention has the following formula (I): P-(S)x-Gal-GA-R, wherein in the P-(S)x-moiety, P is a peptide residue of a human serum glycoprotein and S is a sugar residue of a human serum glycoprotein; Gal is galactose residue; GA is glutaraldehyde residue; x is an integer equal to or greater than 1; and R is a medicinal component selected from the group consisting of interferon, acyclovir sodium, ribavirin, vidarabine, zidovudine, suramin, anti-sense oligonucleotide, ribozyme, leucovorin calcium, sodium-meglumine diatrizoate, gadolinium-DTPA, glutathione (GSH), prostaglandins, ?